Amylyx Pharmaceuticals (AMLX) Share-based Compensation (2021 - 2026)

Amylyx Pharmaceuticals' Share-based Compensation history runs 6 years deep, the most recent figure standing at $12.3 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 79.98% year-over-year to $12.3 million in Q1 2026; TTM through Mar 2026 was $12.3 million, a 58.93% decrease from a year earlier, with the FY2025 full-year figure at $27.6 million, down 16.32% from the prior year.
• Share-based Compensation grew to $12.3 million in Q1 2026 per AMLX's latest filing, from $6.4 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $23.9 million in Q3 2025 and bottomed at $5.0 million in Q1 2022.
• The 5-year median for Share-based Compensation is $7.5 million (2023), against an average of $9.4 million.
• Across the five-year window, Share-based Compensation jumped 1435.84% in 2022 and tumbled 43.1% in 2023, its largest moves.
• Year by year, Share-based Compensation stood at $16.8 million in 2022, then plunged by 43.1% to $9.5 million in 2023, then declined by 29.3% to $6.7 million in 2024, then slipped by 5.27% to $6.4 million in 2025, then soared by 92.58% to $12.3 million in 2026.
• Per Business Quant, the three latest AMLX Share-based Compensation figures stand at $12.3 million (Q1 2026), $6.4 million (Q4 2025), and $23.9 million (Q3 2025).